ATLPD0000075
Product-level evidence profile for identity and molecular form, PK exposure, clinical context, safety context, label material, and reproducible data access.
Formulation context: Injection, powder, lyophilized
Product identity and molecular form, PK exposure evidence, safety context, clinical and label context, interpretation boundaries, and reproducibility exits available for this product.
What is this product, which peptide does it map to, and what is its structure?
What is the drug used for and how does it act?
Are there curated exposure / PK summaries or cited observations?
What safety, postmarketing, and immune-recognition signals surround the product?
What trial and product-label context is attached to this product?
How is the evidence scoped, traced, cited, and reopened?
What the product is, how its complete molecular form is defined, and which chemical or structural representations support that identity.
This product identity anchors product-level label, trial, postmarketing, and PK context. Route, form, and holder fields are shown when they are normalized from product or label references, not inferred from the product name.
These anchors support product-level lookup and context attachment. They are identity evidence, not ADMET endpoint measurements.
ATC classification © WHO Collaborating Centre for Drug Statistics Methodology; used unmodified for non-commercial research.
Product-level label, safety, trial, and PK context may be read beside the linked peptide identity. Endpoint truth still remains controlled by endpoint-specific evidence and compatibility rules.
The public link view emphasizes sequence, identity role, reference support, and interpretation boundary rather than non-public peptide identifiers.
Multiple linked identities can reflect reviewed source-sequence differences, variant entries, or precursor-like entries. Use the reference identity as the main product-context link.
| Identity match | Reference | Link review |
|---|---|---|
| Reference identity | Evidence context | Linked peptide identity |
The link supports product-context interpretation beside a peptide identity. It is not a measured endpoint, and it does not promote label, safety, or trial context into peptide-level endpoint truth by itself.
C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)OStructure shown for the reviewed peptide identity linked to this product (ATLPC0002483). Atom-level 2D depiction rendered from the reviewed SMILES.
A 2D graph describes connectivity, not conformation; a 3D reference describes one coordinate model, not the full ensemble.
Open linked peptide · ATLPC0002483What the drug is used for and how it acts, based on curated therapeutic indications and mechanism-of-action evidence for the product identity.
Traceable exposure and PK properties across product labels, literature, and nonclinical evidence.
Exposure values for the complete product as tested.
Human product-label values are shown first, followed by additional source-backed evidence.
Human exposure properties reported in official product labeling.
Other source-backed PK properties across labels, literature, and nonclinical studies.
Direct source values extend the product's PK endpoint profile.
| PK property | Value | Context | Reference | Measured material | Evidence role | Reported statement |
|---|---|---|---|---|---|---|
| AUC | 1,110 μg*h/mL | human · single 1,200 mg · plasma · patients with ABSSSI | Reference | Reported analyte | Source-reported product-label value | Table 3: Mean (±SD) PK parameters for patients receiving a single ORBACTIV 1,200 mg dose for ABSSSI (n=297) Parameter Mean (±SD) C max , Maximum plasma concentration; AUC 0-24 , Area under the plasma concentration-tim... |
| AUC | 2,800 μg*h/mL | human · single 1,200 mg · plasma · patients with ABSSSI | Reference | Reported analyte | Source-reported product-label value | Table 3: Mean (±SD) PK parameters for patients receiving a single ORBACTIV 1,200 mg dose for ABSSSI (n=297) Parameter Mean (±SD) C max , Maximum plasma concentration; AUC 0-24 , Area under the plasma concentration-tim... |
| AUC | Exposures of oritavancin in skin blister fluid were approximately 20% of those in plasma (AUC 0-24 ) after single 800 mg dose in healthy subjects. | human · plasma | Reference | Reported analyte | Source-reported observation | Exposures of oritavancin in skin blister fluid were approximately 20% of those in plasma (AUC 0-24 ) after single 800 mg dose in healthy subjects. |
| AUC | 1,460 μg*h/mL | context not reported | Reference | Reported analyte | Source-reported product-label value | Table 3: Mean (±SD) Pharmacokinetic Parameters following a single 1,200 mg dose of KIMYRSA by intravenous infusion over 1 hour (N= 50) and Oritavancin by intravenous infusion over 3 hours (N=50) in Patients with ABSSS... |
| AUC | Exposures of oritavancin in skin blister fluid were approximately 20% of those in plasma (AUC 0-24 ) after single 800 mg dose in healthy subjects. | human · plasma | Reference | Reported analyte | Source-reported observation | Exposures of oritavancin in skin blister fluid were approximately 20% of those in plasma (AUC 0-24 ) after single 800 mg dose in healthy subjects. |
| Bioavailability | 110 % | human · intravenous infusion · 1200 mg · KIMYRSA new formulation; 1-hour infusion · plasma · adult subjects with ABSSSI | Reference | Whole product | Curated comparable measurement | Reference entry retained for traceability. |
| Bioavailability | 107 % | human · intravenous infusion · 1200 mg · KIMYRSA new formulation; 1-hour infusion · plasma · adult subjects with ABSSSI | Reference | Whole product | Curated comparable measurement | Reference entry retained for traceability. |
| Bioavailability | Low oral bioavailability due to limited gastrointestinal absorption | oral | Reference | Whole product | Source-reported observation | Reference entry retained for traceability. |
| Clearance | 0.445 L/h | human | Reference | Reported analyte | Source-reported product-label value | Oritavancin has a terminal half-life of approximately 245 hours and a clearance of 0.445 L/h based on population pharmacokinetic analyses. |
| Clearance | 0.445 L/h | human | Reference | Reported analyte | Source-reported product-label value | Oritavancin has a terminal half-life of approximately 245 hours and a clearance of 0.445 L/h, based on population PK analyses. |
Summaries keep species, unit, route, dose, matrix, population, and source context separate. Whole-product values stay attached to the complete product.
Regulatory safety warnings, postmarketing and nonclinical safety context, and immune-recognition context. These describe available signals, not incidence rates or causality.
Clinical-trial context and structured product-label references attached by product identity.
How to read, trace, cite, and reopen this profile: evidence scope, reference lineage, and reproducible data access.
Endpoint summaries, product-context lanes, identity links, and source references answer different questions. This boundary keeps the page useful without converting context into stronger claims than the current review layer supports.
Compare PK results only when endpoint and experimental context are compatible.
Label, trial, safety, immune, and nonclinical records remain contextual unless separately extracted as an endpoint.
Defined molecular entity
Comparable measurement layer
Endpoint-level interpretation when context fields match.
Pooled product parameters across mismatched species, units, route, dose, matrix, population, or source context.
Clinical, label, safety, immune, and nonclinical context
Reading the product's evidence surroundings and source-backed context lanes.
Incidence rates, causality claims, product safety ranking, or normalized ADMET endpoint values.
Molecular identity context
Reading product context beside a reviewed peptide identity.
Automatic transfer of every product-level signal to peptide-level endpoint evidence.
Reproducibility and source trace
Checking where labels, trials, safety reports, identity links, and curated measurements came from.
A substitute for normalized evidence, context grouping, or endpoint review.
Original-source reading path
Reading the source reference in its native regulatory, registry, literature, or source context.
Bypassing ADMETatlas curation status, interpretation boundaries, or endpoint-promotion policy.
Label, trial, safety, immune, identity-link, and PK evidence enter the product profile through different review paths. This module keeps their roles visible so users can trace evidence without over-reading context counts.
active reference families
source-matching traces
PK plus context entries
current product profile
Regulatory product-label context
Label sections, label-derived PK statements, safety wording, route, formulation, and immunogenicity context when extracted.
Label material supports product context. It becomes endpoint evidence only through the reviewed PK or endpoint extraction path.
Human study-registration context
Trial identity, phase/status, intervention matching, and availability of results context around the product.
Trial registry entries are study context unless endpoint-compatible results are extracted and reviewed separately.
Safety surveillance context
Signal-aware reading of reported adverse-event context around marketed products.
Report counts do not establish causality, incidence, or comparative product safety.
Assay and nonclinical support context
Immune-recognition assays, nonclinical safety context, and neighboring signals that help interpret the product profile.
These entries are not clinical incidence or endpoint truth unless a review policy promotes a specific endpoint.
Named-product identity support
Matching named and dosed product presentations to a stable medication identity.
Identity records do not provide an endpoint value, administration outcome, or route-specific clinical result.
Source-matching and identity-review context
Source records used to assess product-to-peptide identity relationships and retained audit context.
Only an exact match to the current authoritative canonical identity supports a linked identity; all other traces remain product context.
Endpoint measurement trace
Rechecking source values, units, route, dose, matrix, population, and source context for PK summaries.
PK entries remain context-bound measurements and should not be pooled across incompatible contexts.
Link references and selected label entries carry direct source links. Product-context entries may instead carry source labels and curated summaries in the structured profile. Both are provenance, but only direct reference fields should be displayed as citation links.
The structured profile access reopens the same product view used by this page, including molecular identity, PK evidence, product context, and reference lineage for the current public release.
public product profile
identity link scope
cited measurement trace
21 context · 2 identity support
label plus link traces
Use the product profile access for product-specific reproducibility. Use full-release downloads for catalog-scale analysis, with the current source policy and data dictionary.
Current product
Machine-readable profile for molecular identity, PK evidence summaries, product context, and reference lineage.
Uses the public ATL product ID in the URL. Non-public product identifiers remain outside the navigation label.
The request returns the structured product profile used by this page. It is the current product-specific reproducibility path while product-only tabular exports remain a release follow-up.
curl -sS 'https://admetatlas.scbdd.com/api/v1/products/ATLPD0000075' \
-H 'accept: application/json' \
-H 'X-Visibility: public_release'Use this module to reproduce the current product profile and locate full-release exports. Cross-product comparison still depends on compatible endpoint, species, route, dose, matrix, population, source, identity-link, and review context.